What Is the Role of CCR3 in Choroidal Neovascularization?

  • Yiwen LiEmail author
  • Deqiang Huang
  • Xin Xia
  • Zhengying Wang
  • Lingyu Luo
  • Rong Wen
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 723)


Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized countries. The “wet” AMD, characterized by the development of choroidal neovacularization (CNV), could result in rapid and severe loss of central vision. The critical role of vascular endothelial growth factor A (VEGF) in CNV development has been clearly demonstrated and clinically VEGF neutralization has become standard care for wet AMD. Recently, CCR3 was reported to play an important role in CNV development and CCR3 targeting was believed to be superior to VEGF targeting for CNV suppression. Our data in the present work show that blocking CCR3 by a small molecule CCR3 antagonist SB 328437 or CCR3-neutralizing antibodies does not inhibit CNV in the Matrigel CNV models of rat and mouse, whereas VEGF-neutralizing antibodies or rapamycin effectively suppresses CNV. These results question the role of CCR3 in CNV development and the therapeutic approach to suppress CNV by CCR3 targeting.


CNV Matrigel CCR3 SB328437 AMD Angiogenesis VEGF-A Rapamycin 



This work was supported by grants from the James and Esther King Biomedical Research Program of the State of Florida (YL), National Institutes of Health (R01EY015289 to RW, R01EY018586 to RW), Hope for Vision (RW), and the Department of Defense (W81XWH-09-1-0674 to RW). It was also supported by NIH core grant P30EY14801 and an unrestricted grant from Research to Prevent Blindness Inc. to Bascom Palmer Eye Institute.


  1. Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444PubMedCrossRefGoogle Scholar
  2. Cao J, Zhao L, Li Y et al (2010) A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF Trap. Invest Ophthalmol Vis Sci 51:6009–6017PubMedCrossRefGoogle Scholar
  3. Chappelow AV, Kaiser PK (2008) Neovascular age-related macular degeneration: potential therapies. Drugs 68:1029–1036PubMedCrossRefGoogle Scholar
  4. Das A, McGuire PG (2003) Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 22:721–748PubMedCrossRefGoogle Scholar
  5. Dejneka NS, Kuroki AM, Fosnot J et al (2004) Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis 10:964–972PubMedGoogle Scholar
  6. Emerson MV, Lauer AK (2007) Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs 21:245–257PubMedCrossRefGoogle Scholar
  7. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4–25PubMedCrossRefGoogle Scholar
  8. Grisanti S, Tatar O (2008) The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 27:372–390PubMedCrossRefGoogle Scholar
  9. Klein R, Klein BE, Linton KL (1992) Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99:933–943PubMedGoogle Scholar
  10. Kwak N, Okamoto N, Wood JM et al (2000) VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41:3158–3164PubMedGoogle Scholar
  11. Li Y, Song Y, Zhao L et al (2008) Direct labeling and visualization of blood vessels with lipophilic carbocyanine dye DiI. Nat Protoc 3:1703–1708PubMedCrossRefGoogle Scholar
  12. Lin RC, Rosenfeld PJ (2007) Antiangiogenic therapy in neovascular age-related macular degeneration. Int Ophthalmol Clin 47:117–137PubMedCrossRefGoogle Scholar
  13. Penn JS, Madan A, Caldwell RB et al (2008) Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27:331–371PubMedCrossRefGoogle Scholar
  14. Qiu G, Stewart JM, Sadda S et al (2006) A new model of experimental subretinal neovascularization in the rabbit. Exp Eye Res 83:141–152PubMedCrossRefGoogle Scholar
  15. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431PubMedCrossRefGoogle Scholar
  16. Rosenfeld PJ, Schwartz SD, Blumenkranz MS et al (2005) Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112:1048–1053PubMedCrossRefGoogle Scholar
  17. Saishin Y, Takahashi K, Limae Silva R et al (2003) VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 195:241–248PubMedCrossRefGoogle Scholar
  18. Takeda A, Baffi JZ, Kleinman ME et al (2009) CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 460:225–230PubMedCrossRefGoogle Scholar
  19. Wen et al (2002) IOVS 2002; 43:ARVO E-abstract 1297Google Scholar
  20. Zhao L, Wang Z, Liu Y et al (2007) Translocation of the retinal pigment epithelium and formation of sub-retinal pigment epithelium deposit induced by subretinal deposit. Mol Vis 13:873–880PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Yiwen Li
    • 1
    Email author
  • Deqiang Huang
    • 1
  • Xin Xia
    • 1
  • Zhengying Wang
    • 1
  • Lingyu Luo
    • 1
  • Rong Wen
    • 1
  1. 1.Bascom Palmer Eye InstituteUniversity of Miami, Miller School of MedicineMiamiUSA

Personalised recommendations